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Abstract
Background Gout arthritis associates with many 
comorbodities such as hyperuricemia, hypertension, 
hyperglycemia, obesity, and dyslipidemia, which are 
also factors for the development of/or predisposition 
factors of chronic kidney diseases (CKD). Albuminuria is 
a predictor factors for CKD. Screening for albuminuria is 
needed to be done in patients with high risk of CKD. This 
research was conducted to examine the prevalence of 
albuminuria and the associated factors in gout arthritis 
patients. 
Methods This research was a cross-sectional study 
from gout arthritis patients’ medical records in Cipto 
Mangunkusumo Hospital. We included all gout patients 
who treated within 2011−2015. Subjects with 
chronic kidney disease, in kidney replacement therapy, 
hypertension ≥ 10 years, and diabetes ≥ 5 years were 
excluded. Albuminuria was determined by urine dipstick 
result of protein ≥ 1+. Factors associated were age, 
sex, hyperuricemia, hypertension, stage of hypertension, 
hyperglycemia, obesity, dyslipidemia, uric acid level, and 
body mass index (BMI). Data associated with the factors 
were recorded and the associations were tested with 
chi square, fisher’s exact, or independent t-test.
Results from 54 subjects included in this research, 
the prevalence of albuminuria was 20.4%. There were 
no significant associations between all factors and 
albuminuria tested by chi square and fisher’s exact test. 
Independent t-test’s results also showed no significant 
associations between all the factors and albuminuria
Conclusion The prevalence of albuminuria in gout 
arthritis patient was 20.4%. There were no significant 
associatons between age, sex, hyperuricemia, 
hypertension, hyperglycemia, obesity, dyslipidemia, 
uric acid level, and body mass index (BMI) tested 
with albuminuria in gout arthritis patients in Cipto 
Mangunkusumo Hospital from 2011−2015.
Keywords: Prevalence, Albuminuria, Gout Arthritis, Risk 
Factors
Introduction
Gout arthritis is a common disease in Indonesia, 
1.7% male population suffer from this disease.1 
Gout arthritis is caused by the precipitation of 
uric acid in joints occured in hyperuricemic 
patients. Hyperuricemia is defined when plasma 
uric acid level reaches ≥ 6.8 mg/dL in normal 
body temperature.2 The precipitation will lead 
inflammation involving complement system 
activation and phagocytosis. Activation of 
complement system makes neutrophils attracted 
to get out to synovial fluid compartment, while 
phagocytosis leads production of IL-1β through 
the activation of NLRP3 inflammasome. IL-1β 
will increase the proliferation, differentiation, 
and apoptosis of cells, and the influx of neutrofil 
to synovial fluid compartement. These processes 
will induce continuous inflammation, and lead the 
release of matrix metalloproteinase (MMP), an 
enzyme that can erode the bones.2,3 
There are 4 phases of gout arthritis: 
asymptomatic, acute gout, intercritical phase, and 
chronic gout. Acute phase or gout attacks happens 
several hours with clinical symptoms, includes 
swollen joint and sharp pain in metatarsophalangeal 
I, ankle, achilles, knee, wrist, fingers, or elbow. 
The attack will be followed by resolution phase. 
Intercritical phase is an asymptomatic phase 
between two attacks. In several cases, intercritical 
phase are not found between the attacks, thus the 
phase is classified as chronic phase. In chronic 
phase, tophi can be developed in fingers, hands, 
knees, ankles, elbows, and antihelix.4 
Gout arthritis decreases the patients’  life 
quality, 21.1% of the patients suffer from moderate 
disability.5 Gout arthritis and hyperuricemia 
could also induce kidney injury that will lead 
to a chronic kidney disease. Gout nephrolitiasis 
and urate nephropathy are the etiology of kidney 
injury in gout arthritis and hyperuricemic patients.6 
Moreover, chronic kidney disease (CKD) is the 
most prevalent comorbidities of gout patients in 
Indonesia (53.08%).7 The previous statement were 
supported by the studies conducted by Roughley 
MJ, et al. 8 and Krishnan, et al. 9 The incidence 
of kidney injury was increasing three times in the 
group with serum uric acid  ≥ 9.0 mg/dL and twice 
in the 7.0−8.9 mg/dL group.10
Gout patients often have comorbidities such as 
hypertension, dyslipidemia, diabetes, and obesity, 
which could increase the risk of developing kidney 
disease.9 Hypertension may induce arteriolopathy, 
glomerulosclerosis, and tubulointerstitial 
fibrosis, whereas hyperglycemia in diabetic 
patients could lead to diffuse mesangial sclerosis, 
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hypertrophy of mesangium cells, and membrane thickening 
glomerulopathy.11–13 Dyslipidemia and obesity can increase 
the release of free radicals that could damage glomeruli 
capilers and mesangium cells, thus leading kidney injury.14,15 
These conditions show us that gout patients are vulnerable to 
develop kidney injury and chronic kidney disease. Therefore, 
screening for chronic kidney disease is needed to be performed 
in all gout patients. Albuminuria is known as a screening 
tool for CKD and end-stage renal disease.16–18 The usage of 
urine dipstick with albuminuria category ≥ +1 is reported as 
good as albumin-creatinin ratio with category ≥ 30 mg/g.19,20 
Therefore, we decided to conduct this research to find out the 
prevalence of albuminuria and risk factors associated in gout 
arthritis patients in RSUPN Cipto Mangunkusumo.
Methods
This is a cross sectional study, done using secondary data 
from medical records of all patients who have diagnosed 
gout and treated in RSUPN Cipto Mangunkusumo between 
January 2011 and December 2015. Gout diagnosis is made by 
the rheumatologists and given code as ICD 10 (International 
Classification of Disease 10) of M10.0. Gout was diagnosis 
using diagnostic criteria in RSUPN Cipto Mangunkusumo 
which is also adapted from American College of Rheumatology 
Guideline in 1987. Patients who have history of chronic kidney 
disease consistent with KDIGO criteria (the presence of 
kidney injury and/or GFR < 60 ml/min/1.73 m2) prior or at the 
time when gout arthritis diagnosis made, history of diabetes 
mellitus ≥5 years, history of hypertension ≥10 years, and no 
data of dipstick urinalysis were excluded from this study. 
Data collected were included age when diagnosus was 
made, sex, weight, height, body mass index (BMI), serum 
uric acid (sUA), blood glucose test (HbA1C, random blood 
glucose, fasting blood glucose, or 2-hours-post-prandial 
blood glucose), blood lipid test (HDL, LDL, total cholesterol, 
or triglyceride), blood pressure test, dipstick urinalysis test, 
history of hypertension, diabetes, dyslipidemia or other 
illnesses, and previous treatment related to gout arthritis and 
its risk factors. 
Independent variables in this study were risk factors in 
2 types of data: categorical and numerical. Risk factors in 
categorical data were defined as: sex (men/women), age (>60 
years old / ≤ 60 years old), hyperuricemia (severe = sUA ≥9.0 
mg/dL, mild = sUA 7.0−8.9 mg/dL, and normal = <7.0 mg/
dL), obesity (BMI  ≥ 25 kg/m2), hypertension (history of 
hypertension or consumption of hypotension agent), stage 
of hypertension (Stage I = systolic pressure < 160 mmHg or 
diastolic pressure <100 mmHg, Stage II = systolic pressure ≥ 
160 mmHg atau diastolic pressure ≥ 100 mmHg), dyslipidemia 
(total cholesterol ≥ 240 mg/dL or LDL ≥ 160 mg/dL or HDL < 
40 mg/dL or trigliserida ≥150 mg/dL or history of dyslipidemia 
or consumption of hypolipidemic agents), and hyperglycemia 
(2-hr PP ≥ 140 mg/dL or FBG ≥ 100 mg/dL or RBG ≥200 
mg/dL or HbA1C >5.6% or history of diabetes mellitus or 
consumption of hypoglycemic agents).10,22–28 Risk factors in 
numerical data were serum uric acid, body mass index, and 
age. The dependent variabel  was albuminuria, defined as 
urine dipstick ≥ +1 with categorical data (yes/no).18–20
All data were recorded in secondary data form made by 
researcher and then inserted in statistical packages for social 
sc i e n c e s  ( S P S S )  for windows version 20.0. Independent 
t-test was used to analyze numerical-categorical data. Chi 
square test was used to analyze categorical-categorical data. 
Fisher’s exact test was used if the data did not meet the criteria 
to be analyzed by chi square test.
Result
There were 191 patients who were diagnosed with gout or 
ICD 10 M10.0 during period January 2011 – December 2015, 
137 samples were excluded consistent to exclusion criteria. 
Excluded samples were mainly due to the lack of urine dipstick 
data and had developed chronic kidney disease prior to the 
study. Other 54 patients was accounted as subjects. From 
these subjects, 40.4% suffered from gout arthritis less than 1 
month, while 25.0% had chronic gout (more than 5 years). 
Tophi were developed in 38.9% subjects. Major subjects were 
male (88.9%) and aged below 60 years old (79.6%), with 
mean age was 50.80 ± 13.05 years old. Severe hyperuricemia 
was found in 30 subjects (58.8%) with mean serum uric acid 
level was 9.27 ± 2.82 mg/dL. Most subjects also suffered 
from dyslipidemia (72.2%). Hypertension found in 50% of 
subjects, 44% of them were stage-2 hypertension. As many as 
40.7% of subjects suffered from hyperglycemia, while obesity 
happened in 44.4% of subjects, with the mean BMI was 26.69 
± 5.17 kg/m2. The prevalence of albuminuria in gout arthritis 
patients was 20.4% (table 1).
Table 1. Characteristics of Gout Arthritis Patients in RSUPN 
Cipto Mangunkusumo in 2011−2015
Characteristics N (%)
Age 
> 60 year-old 11 (20.4%)
≤ 60 year-old 43 (79.6%)
Sex
Men 48 (88.9%)
Hyperuricemia
Severe (≥ 9.0 mg/dL)
Mild (7.0-8.9 mg/dL)
Normal (< 7.0 mg/dL)
No data
30 (58.8%)
10 (19.6%)
11 (21.6%)
3
Hypertension 27 (50.0%)
Stage 1
Stage 2
No data
8 (40.0%)
12 (60.0%)
7
Hyperglycemia 22 (40.7%)
Obesity
Dyslipidemia
24 (44.4%)
39 (72.2%)
Albuminuria 11 (20.4%)
Duration of Illness
< 1 month
1-6 months
6-12 months
1-3 years
3-5 years
> 5 years
     Missing data
21 (40.4%)
1 (1.9%)
7 (13.5%)
4 (7.7%)
6 (11.5%)
13 (25.0%)
2
Tophus 21 (38.9%)
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Allopurinol was the most prescribed medicine for 
subjects (33 patients). Metyhlprednisolone and colchicine 
were two other agents that were prescribed less frequent 
then NSAID in order to reduce the inflammation occurred in 
acute attack (figure 1). For hypertension treatment given to 
27 subjects, angiotensin-converting enzyme inhibitor was the 
most anti-hypertensive agent used. Most patients (56.4%) with 
dyslipidemia frequently got statins rather than other agents.
Figure 1. Treatment Characteristics for Gout Arthritis Patients in 
RSUPN Cipto Mangunkusumo in 2011-2015
Tabel 2. Associations between Age, BMI, and Serum Uric Acid 
with Albuminuria
Risk 
factors
Albuminuria
p value
Mean difference 
(95% CI)
Yes
(N,%)
No
(N,%)
Age 56.00 ± 12.47 
(11, 20.4%)
49.47 ± 13.00
(43, 79.6%)
0.140 6.53
(-2.21 – 15.28)
UA 9.98 ± 2.94 
(9, 17.7%)
9.12 ± 2.80 
(42, 82.3% )
0.411 0.86
(-1.23 – 2.94)
BMI 23.81 ± 2.89 
(8,18.6%)
27.35 ± 5.37 
(35,81.4%)
0.071 - 3.54
( -7.52 – 0.45)
UA: Serum Uric Acid; BMI: Body Mass Index
Table 3. Associations between Risk Factors and Albuminuria and 
the Statistical Test Used
Risk Factors
Albuminuria
Yes 
N (%)
No
N (%)
p OR (95% CI)
Age 
> 60 years old 4 (36.%) 7 (63%) 0.206 2.939 
(0.675−12.798)≤ 60 years old 7 (16.3%) 36 (83.7%)
Sex
Men
Women
10 (20.8%)
1 (16.7%)
38 (79.2%)
5 (83.3%)
1.000 1.316 
(0.38−12.574)
Hyperuricemia
Severe 
Mild and normal
Missing data
6 (20.0%)
3 (14.3%)
3
24 (80.0%)
18 (85.7%)
0.720 1.500
 (0.330−6.822)
Risk Factors
Albuminuria
Yes 
N (%)
No
N (%)
p OR (95% CI)
Stage of 
Hypertension
Controlled and 
Stage 1
Stage 2
0 (0.0%)
4 (33.3%)
8 (100.0%)
8 (66.7%)
0.118 Could not be 
computed*
Hyperglycemia
Yes
No
5 (22.7%)
6 (18.8%)
17 (77.3%)
26 (81.2%)
0.721 1.275 
(0.335−4.843)
Obesity
Yes
No
Missing data
Dyslipidemia
Yes
No
2 (8.3%)
6 (31.6%)
11
9 (23.1%)
2 (13.3%)
22 (91.7%)
13 (68.4%)
30 (76.9%)
13 (86.7%)
0.111
0.708
0.197 
(0.035−1.123)
1.950 
(0.369−10.304)
Severe hyperuricemia (≥9.0 mg/dL), mild and normal hyperuricemia 
(<9.0 mg/dL)
* The risk of stage of hypertension couldn’t be computed as there was 
one cell that had 0 value
Independent T-test was used to analyze the association 
between age, BMI, and serum uric acid with albuminuria. It 
showed that there were no significant associations between all 
the risk factors with albuminuria (p value >0.05). However, 
there was quite a difference in mean age between the two 
groups (6.53 years; 95% CI -2.21–15.28). Moreover, the 
mean BMI of albuminuria group was lower than the non-
albuminuria group (23.81 ± 2.89 vs 27.35 ± 5.37 kg/m2, 
respectively), making it more interesting because this result 
was contradictive to others (table 2). When other factors 
were analyzed by chi square and fisher’s exact test, there 
were no significant associations between all risk factors and 
albuminuria (table 3).
Discussion
This study showed us that 88.9% subjects were men, which is 
similar to the study conducted by Limanjaya, et al (81.96%).7 
Fewer women suffered from gout arthritis because of the 
estradiol effect which decrease uric acid serum level and 
prevent gout arthritis.29  Most of gout patients were younger 
than 60 years old, with mean age at 50.80 ± 13.05. It is 
consistent  with the previous study which stated the mean gout 
patients at 50.5 ± 13.0 years old,30 and also consistent with 
theory which said that gout arthritis occurred frequently in the 
age of 50s.31 
 The mean of serum uric acid level found in this study 
(9.27 ± 2.82 mg/dL) was higher than in the study by Chen J, 
et al.32 However, this result correlates with gout pathogenesis. 
Patients with uric acid serum more than 8 mg/dL are more 
likely to suffer from monosodium urate crystallization rather 
than patients with lower level of uric acid serum.33 The 
prevalence of hyperuricemia in this study was also higher 
than the previous study conducted in Indonesia by Darmawan, 
et al. which was found only 24.3% patients. The difference 
might be occured because of the different subject population, 
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as we conducted a hospital-based study while this previous 
study conducted a population-based study.1 
Hypertension prevalence in this study was lower than 
Krishnan, et al. (93%) and Choi, et al. (69.1%). It is proved that 
the different of races, lifestyles, and ages of subjects are affected 
the prevalence of hypertension..9,34 However, the prevalence we 
found was higher than general Indonesian population (9.5%). 
This fact showed us that hypertension is more likely to happen 
in gout patients than in general population. It is in accordance 
with the result of study conducted by Yu, et al. (OR 7.21; 
95% CI 7.00−7.44).35,36 The less prevalence showed by this 
study also happened in hyperglycemia (40.7% in this study, 
vs 70.8%, 48.4%, and 53.7% in Chen J, et al, Choi, et al, and 
Fraile, et al, respectively).32,34,37 The difference was caused by 
the different inclusion criteria and targeted population, which 
made the different races, lifestyles and characteristics of other 
illness between these studies.21,38–40 However, the prevalence 
we found was higher than general Indonesian population 
(10.0%).41 It indicates that hyperglycemia is also more likely 
to happen in gout patients than in general population. 
Prevalence of dyslipidemia in subjects (72.2%) was 
higher than Choi, et al study (53.7% for hypertriglyceridemia 
and 47.4% for low HDL level) and than general Indonesia 
population prevalence (48.9% of low HDL level, 33.9% of 
high LDL level, and 24.8% of high total cholesterol level).34,42 
This might be happened due to the different inclusion criteria 
of dyslipidemia used in this study, which include all aspects 
of blood lipid test, thus the findings was bigger. The other 
findings with higher prevalence were also occured in obesity 
(44.4%), with mean BMI is also higher than Chen J, et al study 
(23,5% and mean BMI 25.0 ± 3.2 kg/m2). The difference is 
happened due to the different criteria of obesity used in Chen 
J, et al study which defined obsesity with BMI > 27 kg/m2.32 
The prevalence of albuminuria in this study (20.4%) was 
higher than other studies, such as Yu and Berger (14.9%)43 and 
Kuo, et al (9.8%).44 The difference of population, leads to the 
different races and lifestyles, could explain this difference. 
Asian race is a predisposing factor of albuminuria compared to 
Caucasian (OR 1.42; IK 1.26−1.61).21 Both race and lifestyle 
were risk factors of albuminuria which was not included in 
this study.21,38–40
There were no significant associations between all the 
risk factors with albuminuria. No significat association of 
albuminuria with age, sex, and other hyperuricemia factors 
might be happened due to the characteristic of gout patients. 
Gout patients are tend to be occured at the population with 
age 50s (in ≤ 60 years old group), men, and had severe 
hyperuricemia, with or without albuminuria, thus making it 
difficult to differentiate between the groups. The medications 
given to gout patients, such as allopurinol and colchicine, 
could also disturb the result of this study due to their 
protective effect to the kidney. 45–47 However, the prevalence 
of albuminuria was increasing from 16.3% in ≤ 60 years old 
group to 36.4% in the older group, which is consistent with 
Ramirez, et al. (adjusted OR 2.7; IK 95% 2.2−3.3).48 
We found hyperglycemia had no association with 
albuminuria. This result was different from other studies49,50 
Hyperglycemia in diabetes patients could alter the basal 
membrane of glomerulus after 3−5 years.13,51 The method to 
determine hyperglycemia in this study could not detect a long-
term hyperglycemia condition, so this could be the reason 
why we found no association in this study. Meanwhile, for 
dyslipidemia, since our study used fewer sample size than 
other studies, the different rate of dyslipidemia observed in this 
study (9.8%) can not used to detect a significant difference.26,52 
Moreover, the majority of dyslipidemia patients in this study 
had used statin (56.4%), which could decrease the rate of 
albuminuria or proteinuria.53 
Obesity also did not have any significant association 
with albuminuria. This result is also different from the 
others.50,52 However, the prevalence of albuminuria in obese 
group was lower than in non-obese group (8.3% and 31.6%, 
respectively). The mean BMI of albuminuria group was lower 
than non-albuminuria group. All patients in non-obese group 
which developed albuminuria had other illnesses which were 
associated with albuminuria, such as tuberculosis, chronic 
heart failure, gout nephropathy, pneumonia, and stroke.54–58
Hypertension did not have any significant assosciation 
with albuminuria either. This result was inconsistent with the 
other studies due to the different characteristics of population, 
sample size, and method to determine albuminuria.11,24,50,52 
Moreover, most hypertension patients used angiotensin-
converting enzyme inhibitor (ACEi) and angiotensin 
receptor blocker (ARB) which can decrease the incidence of 
proteinuria and prevent end-stage renal disease (ESRD).59,60 
All albuminuria happened in stage-2 hypertension patients. 
This fact was consistent with the other studies which showed 
that high systolic or/and high diastolic pressure were the risk 
factors of proteinuria.48,61 No significant association observed 
in this study was due to the fewer sample size and the missing 
data. Therefore, we recommend perform a bigger study to 
prove the association between hypertension (high systolic and 
diastolic pressures) and albuminuria in gout arthritis patients.
In spite of the fact that there were no significant association 
between the observed factors and albuminuria, this study 
showed us that there is a lot number of albuminuria occurring 
in gout patients. Since albuminuria has a predictive value 
on chronic kidney disease, the future study should seek the 
association between albuminuria and the incidence of chronic 
kidney disease in gout patients. Moreover, the fact that all 
gout patients who had stage-2 hypertension suffered from 
albuminuria were an indication that systolic and diastolic 
pressures were risk factors of albuminuria in gout patients. 
Therefore, precaution actions should be taken when dealing 
with gout patients who had stage-2 hypertension to prevent the 
progression of albuminuria. Future studies should also address 
the exact limit of blood pressure needed in gout patients in 
order to prevent the occurance of albuminuria and chronic 
kidney disease.
 Lack of significant correlation found in this study was due 
to minimal sample size and data limitation, we do not assess the 
data of lifestyle which potentially confound the result. Thus, 
future studies should have a bigger sample size and measure 
the population’ lifestyle, as well as the other confounders like 
other comorbidities, and medicine taken by subjects. The use 
of other albuminuria test methods (albumin-creatinine ratio or 
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24-hour urine collection) is suggested to get numerical data, 
so that it is possible for future studies to seek the correlation 
between the risk factors and albuminuria more accurately.
Conclusion
The prevalence of albuminuria in gout patients in RSUPN 
Cipto Mangunkusumo in 2011−2015 was 20.4%. There were 
no significant correlation between age, sex, hyperuricemia, 
obesity, hypertension and stage of hypertension, hyperglycemia, 
and dyslipidemia with albuminuria. However, the prevalence 
of albuminuria was considerably high, especially in patients 
who had stage-2 hypertension. Therefore, preventive actions 
to those patients and future studies related to albuminuria’s 
association with chronic kidney disease incidence in gout 
patients are needed.
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